Brevan Howard Capital Management »

Supernus Pharmaceuticals shares owned by Brevan Howard Capital Management

Quarter-by-quarter ownership of Supernus Pharmaceuticals (SUPN) shares owned by Brevan Howard Capital Management from 13F filings

Historical chart of Brevan Howard Capital Management investment in Supernus Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Supernus Pharmaceuticals held by Brevan Howard Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Supernus Pharmaceuticals by Brevan Howard Capital Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $547k 11k 47.79
2025-06-30 $1.1M 36k 31.52
2025-03-31 $1.1M 32k 32.75
2024-12-31 $272k 7.5k 36.16

More positions owned by Brevan Howard Capital Management

Alphabet Cap Stk Cl C Call Option (GOOG)
Ishares Bitcoin Trust Etf Shs Ben Int Call Option (IBIT)
Pdd Holdings Sponsored Ads Call Option (PDD)
Microsoft Corporation Call Option (MSFT)
Meta Platforms Cl A Call Option (META)
Ishares Tr Msci Emg Mkt Etf Call Option (EEM)
Ishares Tr Iboxx Hi Yd Etf Put Option (HYG)
Ishares Tr Iboxx Inv Cp Etf Call Option (LQD)
Dbx Etf Tr Xtrack Hrvst Csi Call Option (ASHR)
NVIDIA Corporation Call Option (NVDA)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Coinbase Global Com Cl A Call Option (COIN)
Baidu Spon Adr Rep A Call Option (BIDU)
Agnico Call Option (AEM)
Alphabet Cap Stk Cl A Put Option (GOOGL)

View all positions for Brevan Howard Capital Management

Top funds holding Supernus Pharmaceuticals

BlackRock
Vanguard Group
Armistice Capital
Dimensional Fund Advisors
Point72 Asset Management
State Street Corporation
Renaissance Technologies
Geode Capital Management
Loomis, Sayles and
Citadel Advisors
Stephens Investment Management Group
Jennifer Ranahan
D. E. Shaw & Co
Charles Schwab Investment Management
Goldman Sachs Group

View all funds holding Supernus Pharmaceuticals